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Irisin is a pro-myogenic factor that induces skeletal
muscle hypertrophy and rescues denervation-
induced atrophy
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Exercise induces expression of the myokine irisin, which is known to promote browning of
white adipose tissue and has been shown to mediate beneﬁcial effects following exercise.
Here we show that irisin induces expression of a number of pro-myogenic and exercise
response genes in myotubes. Irisin increases myogenic differentiation and myoblast fusion
via activation of IL6 signaling. Injection of irisin in mice induces signiﬁcant hypertrophy and
enhances grip strength of uninjured muscle. Following skeletal muscle injury, irisin injection
improves regeneration and induces hypertrophy. The effects of irisin on hypertrophy are due
to activation of satellite cells and enhanced protein synthesis. In addition, irisin injection
rescues loss of skeletal muscle mass following denervation by enhancing satellite cell
activation and reducing protein degradation. These data suggest that irisin functions as
a pro-myogenic factor in mice.
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Skeletal muscle is one of the largest organs in the humanbody. Skeletal muscle is made up of multi-nucleated muscleﬁbers, which are formed by the fusion of myoblasts during
embryonic and fetal development1. During postnatal myogenesis,
muscle stem cells, also known as satellite cells are activated upon
myo-trauma, exercise, or stress to form myoblasts, which differ-
entiate and eventually give rise to new muscle ﬁbers2. Exercise
imparts many health beneﬁts to skeletal muscle. One of the
hallmarks of exercise is induction of hypertrophy of skeletal
muscle. During exercise, muscle ﬁbers undergo necrosis, which
activates satellite cells in order to repair the damaged ﬁbers3.
Hypertrophy of skeletal muscle can be attributed to increased
protein synthesis via the Akt/mTOR pathway4 and also the Erk1/
2 pathway5. Increased phosphorylation of molecules in these
pathways leads to the activation of signal transduction pathways
that increase protein synthesis. Additionally, protein degradation
is inhibited during exercise6, 7. Increased protein synthesis cou-
pled with reduced protein degradation are signiﬁcant contribut-
ing factors to skeletal muscle hypertrophy8, which is consistent
with the exercise phenotype.
Exercise induces the expression of the nuclear transcriptional
co-activator peroxisome proliferator-activated receptor-γ co-
activator-1-α (PGC1-α) in skeletal muscle ﬁbers9. A recent
study revealed that PGC1-α induces the expression of ﬁbronectin
type III domain containing 5 (Fndc5), which encodes for a 209-
amino-acid (aa)-long, type I membrane protein FNDC510. Bos-
tröm et al. further showed that FNDC5 is cleaved at the C ter-
minus to give rise to a 112-aa-long secreted hormone known as
irisin. Irisin induces the expression of “browning genes”, such as
Ucp1, Cidea, Cpt1b, and Dio2, in white adipocytes, which is an
effect partly mediated by peroxisome proliferator-activated
receptor-α10. Upregulation of Ucp1 promotes uncoupling of
oxidative phosphorylation from energy production, resulting in
release of energy as heat via non-shivering thermogenesis and
enhanced browning of white adipose tissue9, 11, 12. Consistent
with this result, secretion of irisin from skeletal muscle during
exercise has been recently shown to have evolved from shivering
thermogenesis, where muscle contracts in order to generate heat
when exposed to the cold13. Although initially identiﬁed as a
myokine, recently it has been shown that small amounts of irisin
are synthesized and secreted from adipose tissue14 and liver15.
While the presence of irisin and increased expression of irisin
in response to exercise has been well established in mouse models,
contrasting results have been reported in humans. Boström
et al.10 noted the presence of irisin in human serum and increased
serum irisin levels in humans after exercise. Rachke et al.
observed that FNDC5 sequence is found in most rodents and
primates, and is conserved throughout the species. However, in
human FNDC5 sequence, the translational start codon ATG is
not conserved and instead ATA, which codes for isoleucine16, is
found. Rachke et al. also reported that upregulation of PGC1-α
mRNA expression by simulating contraction of primary human
myotubes did not show a concomitant increase in the FNDC5
mRNA expression. Furthermore, Rachke et al. failed to observe
an increase in FNDC5 mRNA in either endurance or strength
training (resistance exercise). Hence, they concluded that irisin
may not confer its beneﬁcial effects in humans16. Albrecht et al.
also cast doubts on the presence of circulating irisin since all
previous studies used commercial enzyme-linked immunosorbent
assay (ELISA) kits using polyclonal antibodies that were not
tested previously for irisin speciﬁcity in serum and they could
very well display cross reactivity17.
Jedrychowski et al. then responded very elegantly to these
observations by using tandem mass spectrometry to detect irisin
with control peptides enriched with heavy stable isotopes18. Irisin
was detected at 12 kDa and it was reported that irisin circulates in
the human serum at about 3.6 ng/ml in sedentary individuals and
is increased after aerobic interval training to 4.3 ng/ml. To date
255 publications (Pubmed search) conﬁrm the presence of
human irisin. Hence, it is possible that irisin may also play a
crucial role in metabolism in humans19.
Irisin has been shown to be upregulated by both endurance and
resistance exercise. Furthermore, circulating irisin levels have
been positively correlated with biceps circumference and insulin-
like growth factor-1 levels in humans15. Similarly, in myostatin-
null (Mstn-null) mice with increased musculature, elevated irisin
levels are seen20. In addition, recent work has revealed that irisin
is able to stimulate muscle growth-related genes in humans20. It
has been further shown that irisin levels are increased during
myogenic differentiation and that irisin treatment results in
increased p-Erk expression, which is involved in the protein
synthesis pathway21. Taken together, these studies provide clues
that increased irisin levels could promote skeletal muscle growth.
Since exercise induces FNDC5/irisin expression and promotes
hypertrophy, we hypothesized that recombinant irisin could
potentially induce skeletal muscle hypertrophy and as such will
have therapeutic beneﬁt in overcoming atrophy. In order to
investigate this, we utilized recombinant murine irisin protein.
Here we have shown that irisin promotes myogenic differentia-
tion by improving myoblast fusion. Furthermore, injecting irisin
induced skeletal muscle hypertrophy and enhanced skeletal
muscle regeneration after muscle injury.
Results
Irisin treatment induces the expression of Ucp1. Polyacrylamide
gel electrophoresis (PAGE) and Coomassie blue staining revealed
a single puriﬁed irisin band running at ~ 15 kDa (Fig. 1a). At
1:100 dilution of the puriﬁed recombinant irisin protein, low
endotoxin levels of 1 was found22. In order to test the biological
activity of our recombinant murine irisin protein, we treated
differentiated human adipose-derived stem cells (hADSCs) with
recombinant irisin protein. A signiﬁcant ~4-fold increase in Ucp1
expression was noted in hADSCs after treatment with irisin
(Fig. 1b). We further noted a signiﬁcant ~ 18% increase in Ucp1
expression in irisin-treated 3T3L1 ﬁbroblasts during adipogenic
differentiation (Fig. 1c).
Microarray analysis. To identify gene expression changes
induced by irisin, we performed microarray on RNA isolated
from either dialysis buffer (DB)- or irisin-treated C2C12 myo-
tubes. Only genes that were upregulated or downregulated by ≥
1.5-fold were analyzed for each time point. Of these selected
genes we noted that genes involved in exercise, satellite cell reg-
ulation, skeletal muscle regeneration, muscle growth, and myo-
genesis were differentially expressed between DB- and irisin-
treated myotubes (Table 1). A number of target genes identiﬁed
from the microarray were validated through quantitative real-
time PCR (qPCR). Subsequent qPCR analysis conﬁrmed reduced
expression of negative regulators of myogenic differentiation,
including sox8 (Fig. 1d) and heyL (Fig. 1e), following treatment
with irisin. Moreover, exercise-induced and -secreted factors,
such as haptoglobin (Fig. 1f) and interleukin 6 (il6; Fig. 1g), which
promote skeletal muscle hypertrophy, were signiﬁcantly upregu-
lated by irisin treatment. The expression of Cxcl1, a chemokine
highly expressed in skeletal muscle and secreted during exercise,
was elevated at all time points analyzed, with a sharp signiﬁcant
increase in Cxcl1 noted 6 h post irisin treatment (Fig. 1h).
Another exercise-secreted factor, pentraxin-3 (ptx3) (Fig. 1i)
also showed a marked upregulation at all irisin treatment
time points.
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Irisin enhances myoblast proliferation and fusion. The myo-
blast assay showed a signiﬁcant increase in the number of myo-
blasts at 24, 48, and 72 h of proliferation when treated with irisin.
Moreover, a dose-dependent increase in the number of myoblasts
48 h after treatment with increasing concentrations of irisin (250,
1000, and 2000 ng/ml) was observed when compared to DB-
treated control (Fig. 2a). The optical density (OD) reading at 655
nm was proportional to the number of myoblasts in the different
treatment groups.
To further investigate the effect of irisin on myogenesis,
differentiating C2C12 myotubes were treated with irisin. A
distinct increase in the number of myotubes was noted at both 72
and 96 h of differentiation in C2C12 myotubes treated with irisin,
when compared to DB-treated controls (Fig. 2b, c). The increase
in myotube number could be due to enhanced fusion. Consistent
with this, a marked increase in myoblast fusion index was also
observed at both 72 and 96 h of differentiation following irisin
treatment (Fig. 2d). We further analyzed the gene expression of
fusion markers. Irisin treatment resulted in signiﬁcantly increased
expression of the primary fusion marker, myomaker (Fig. 2e).
Although we observed an increasing trend of the secondary
fusion marker, caveolin-3 (Fig. 2f), the increase was not
statistically signiﬁcant.
We next measured the levels of protein involved in myogenesis.
MyoD, p21, myogenin, and myosin heavy chain (MHC) levels in
proteins obtained from differentiating myotubes at 24, 48, 72, and
96 h treated with DB (control) or irisin were measured (Fig. 2g). We
observed no distinct change in the expression of the myogenic
markers, MyoD (Fig. 2h) and myogenin (Fig. 2j) after treatment with
irisin. However, we observed a signiﬁcant increase in p21 expression
at 96 h (Fig. 2k). We noted an increase in the expression of MHC
from 72 h, which became statistically signiﬁcant at 96 h (Fig. 2i).
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Fig. 1 Irisin induces gene expression changes and improves myogenesis. a Image of Coomassie-stained polyacrylamide gel showing recombinant His-
tagged irisin protein. Recombinant irisin protein was detected as a single band at ~15 kDa. Lane 1 shows the SeeBlue Plus 2 Pre-Stained ladder. Lanes 2, 3,
and 4 show 1, 2, and 5 μl of the puriﬁed His-tagged irisin protein, respectively. b Graph representing qPCR analysis of Ucp1 expression in human
subcutaneous white adipose-derived stem cells (hADSCs) after 21 days of adipogenic differentiation in the presence of DB (control) or irisin (n= 2
biological replicates). c Graph representing qPCR analysis of Ucp1 in 3T3L1 ﬁbroblasts after 4 days of adipogenic differentiation in the presence of DB
(control) or irisin (n= 3 biological replicates). Graphs displaying qPCR analysis of sox8 (d), heyL (e), haptoglobin (f), il6 (g), cxcl1 (h), and ptx3 (i) in 72 h-
differentiated C2C12 myotubes treated with DB (control) or recombinant irisin protein for 0, 6, 12, 24, and 48 h. All qPCR graphs show gene expression
normalized to gapdh (n= 3 biological replicates). Error bars represent mean± SEM. Student’s t-test was performed for b and all relevant ﬁgure panels
between d and i, and one-way ANOVA was peformed for c. Signiﬁcance is indicated with *p< 0.05, **p< 0.01 and ***p< 0.001
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To understand if recombinant murine irisin protein would
result in a similar phenotype in humans, we treated differentiat-
ing 36C15Q primary human myotubes with DB or increasing
concentrations of irisin (250 and 1000 ng/ml) (Fig. 3a). A
signiﬁcant increase in the myotube number at 48 and 72 h was
observed (Fig. 3b). Fusion index of differentiating myotubes was
also enhanced signiﬁcantly at 48, 72, and 96 h (Fig. 3c). Our
results suggest that recombinant irisin enhances myogenesis in
both mouse and human myotubes.
Irisin injection induces muscle hypertrophy. We injected 5-
week-old mice with either DB or recombinant irisin protein.
Quantiﬁcation of circulating irisin revealed that there was a sig-
niﬁcant increase in irisin levels in mice injected with irisin
(~ 320 ng/ml) when compared to DB-injected mice (~ 213 ng/ml)
(Fig. 4a). As expected, injection of irisin increased Ucp1 levels by
~ 4-fold in subcutaneous adipose tissue (Fig. 4b(i), (ii)). Irisin
injection did not cause signiﬁcant difference in food consump-
tion. Body weights increased in both DB- and irisin-injected mice
across the 4-week regimen (Fig. 4c). However, the percentage
change in body weight was noticeably greater and more rapid in
irisin-injected mice when compared to DB-injected mice (Fig. 4c).
A signiﬁcant increase in Quad, M. biceps femoris (BF), M. tibialis
anterior (TA), and M. extensor digitorum longus (EDL) muscle
weights was seen in mice injected with irisin, when compared to
control (Fig. 4d, e). Measurement of grip strength further indi-
cated that the increased muscle mass translated into enhanced
grip strength in mice injected with irisin (Fig. 4f). Histological
analysis clearly revealed noticeable hypertrophy of myoﬁbers
upon irisin injection (Fig. 4g). A marked reduction in the number
of myoﬁbers with smaller cross-sectional area (CSA; < 2000 µm2),
concomitant with a distinct increase in the number of myoﬁbers
with larger CSA (>2000 µm2), was noted in irisin-injected mice
(Fig. 4h).
We did not observe any signiﬁcant change in the percentage
change of the body weights of mice injected with either DB
(control) or His-tag peptide (Fig. 4i). Furthermore, there was no
signiﬁcant difference in the hindlimb muscle weights between
DB- and His-tag peptide-injected mice (Fig. 4j, k). The
histological analysis further conﬁrmed that there was no
signiﬁcant difference in the CSA of muscle ﬁbers between TA
muscles extracted from DB- or His-tag peptide-injected mice
(Fig. 4l, m).
We next analyzed the levels of components of three main
pathways that activate protein synthesis; Akt, mTOR and Erk1/2,
since the activation of these pathways has been shown to promote
skeletal muscle hypertrophy4. Treatment of C2C12 myotubes
with recombinant irisin protein resulted in a signiﬁcant increase
in the levels of p-Akt (Ser473) (Fig. 5a). As p-Akt in turn activates
mTOR, we next analyzed the activity of mTOR by studying the
phosphorylation of Raptor. We noted a signiﬁcant reduction in
the phosphorylation of Raptor (Ser792) upon treatment with
irisin (Fig. 5a), which is indicative of mTOR activation. Irisin
treatment also resulted in a signiﬁcant increase in the levels of
active p-Erk1/2 (Fig. 5a). Taken together these data suggest that
irisin promotes skeletal muscle hypertrophy through activating
pathways that promote protein synthesis.
As the Akt pathway is closely linked to protein degradation23
through ubiquitination, we next analyzed the levels of p-FoxO1,
Atrogin-1, and MuRF-1 in irisin-treated myotubes. Subsequent
analysis revealed increased levels of inactive p-FoxO1 following
treatment with recombinant irisin protein (Fig. 5b). Although the
increased p-FoxO1 expression was not statistically signiﬁcant, we
observed a signiﬁcant reduction in the levels of Atrogin-1
(Fig. 5b) and MuRF-1 (Fig. 5b) following irisin treatment. These
data reveal that irisin not only increases anabolism but may also
reduce catabolic pathways in skeletal muscle.
Irisin signals via the IL6 pathway during myogenesis. Gene
expression analysis on RNA from irisin-treated myoblasts
revealed that irisin treatment resulted in a signiﬁcant increase in
Table 1 Irisin treatment promotes the expression of pro-
myogenic and exercise-related genes in myotubes
Exercise regulated Gene
(symbol)
6 h 12 h 24 h 48 h
Upregulated Cxcl1 142.7 153.0 76.8 93.1
Cd74 2.6 2.7 3.5 3.0
Nrg1 — — 1.8 2.9
Nrp — — — 2.9
Thbd 1.5 2.0 1.5 2.4
Gap43 −1.6 — — 2.3
Socs3 — 2.1 3.1 2.2
Ccnd1 2.4 — — −1.6
Tiparp — — 2.9 —
Sod3 2.3 2.4 1.7 —
Timp1 2.1 1.6 — 1.5
Mmp10 3.3 — — —
Hp — 1.8 3.4 —
Prdx6 — −1.5 3.3 —
Ptx3 2.5 5.1 8.9 6.8
Downregulated Crispld2 −1.8 — −3.0 −3.5
Cobll1 — −1.6 −2.6 —
Irak4 — — −1.6 —
Gpd1l — −2.1 — —
Pdgfb — — −1.6 −1.6
Satellite cell
regulation
Gene
(symbol)
6 h 12 h 24 h 48 h
Inhibit
differentiation of
satellite cells
Heyl −2.9 −3.6 −3.1 −3.4
Ogn −2.3 −1.5 −1.9 −1.6
Sox8 −1.5 −2.0 −2.6 −1.6
Skeletal muscle
regeneration
Gene
(symbol)
6 h 12 h 24 h 48 h
Upregulated C1s 1.6 1.6 1.8 3.9
Ccl2 38.5 40.7 13.2 3.9
Ccl7 10.4 18.7 7.6 4.9
Cxcl16 10.6 10.8 7.4 3.2
Mmp9 22.6 10.6 5.2 —
Ereg 3.5 — — —
Figf −1.6 2.6 2.2 1.9
Mt1 2.9 2.3 1.9 1.7
Cxcl12 — 2.8 4.3 2.5
Megf10 −1.6 −1.8 −1.7 −2.0
Downregulated Plau −1.8 −2.0 −1.6 —
Muscle growth and
myogenesis
Gene
(symbol)
6 h 12 h 24 h 48 h
Hypertrophy and
growth factors
Sema3f 1.8 — 1.5 1.6
Il6 6.4 6.7 2.5 3.6
Il6ra 1.6 —
Shq1 2.4 — — —
Il7 2.0 1.5 1.7 2.4
Serpina3g 17.8 7.1 8.4 7.9
Tgfbi — — 1.7 2.4
Bmp4 −4.3 1.9 2.6 2.1
Tnfrsf11b — — 2.0 1.7
Agxt2 — 2.6 3.4 —
Table listing differentially expressed genes, identiﬁed through microarray analysis, between
myotubes treated with either DB (control) or irisin for 6, 12, 24, and 48 h. Genes have been
manually separated into exercise regulated, satellite cell regulation, skeletal muscle
regeneration, and muscle growth and myogenesis categories. Gene symbols and fold changes at
each treatment time point are given. Negative numbers reﬂect fold repression of gene
expression. Only genes that were upregulated or downregulated by ≥ 1.5-fold were selected
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IL6, after 24 h of treatment (Fig. 6a). Consistent with this result,
we also observed a signiﬁcant increase in the expression of Stat3,
a downstream target of IL6, after 24 h of irisin treatment (Fig. 6b).
Socs3, a negative regulator of the IL6 pathway, is known to be
upregulated after IL6 activation24. Consistent with this, we
observed an upregulation of Socs3 expression at 24, 48, and 72 h
of proliferation with irisin treatment (Fig. 6c). Similar to
myoblasts, irisin treatment increased IL6 expression over the time
course of differentiation in myotubes (Fig. 6d). Unlike IL6
expression, irisin treatment did not signiﬁcantly increase Stat3
expression in myotubes. However, an increasing trend in Stat3
expression in response to irisin was observed (Fig. 6e). An
increase in Socs3 expression at 24 h of irisin treatment was seen
and not thereafter (Fig. 6f).
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To further probe the involvement of IL6 in irisin signaling, we
knocked down IL6 in differentiating myoblasts and queried if
irisin is effective in enhancing myogenesis in the absence of IL6.
Treatment with IL6-speciﬁc siRNA (IL6 siRNA), but not with
control scrambled siRNA (scramb-siRNA), was very effective in
the knockdown (~80% downregulation) of IL6 mRNA levels at
the 48 h time point (Fig. 6g). While irisin treatment induced
signiﬁcant levels of IL6 in scramb-siRNA-transfected myotubes at
48 h time point, there was a signiﬁcant inhibition in irisin-
mediated induction of IL6 in the presence of IL6 siRNA (Fig. 6g).
To further validate the role of IL6 in the irisin signaling
pathway, we performed a differentiation assay on myotubes
transfected with IL6 siRNA or control scramb-siRNA and treated
with either DB (control) or irisin for 72 h (Fig. 6h). Both fusion
index and myotube number showed a signiﬁcant increase in the
scramb-siRNA-transfected + irisin-treated myotubes as compared
to the scramb-siRNA-transfected + DB-treated myotubes
(Fig. 6i, j), which further validates the results obtained in the
differentiation assay (Fig. 2c, d). Knockdown of IL6 in myotubes
resulted in impaired differentiation and hence, fusion index
(Fig. 6i) and myotube number (Fig. 6j) was reduced in IL6
siRNA-transfected myotubes. It is noteworthy that irisin-treated
IL6 siRNA-transfected myotubes also showed a reduction in
fusion index (Fig. 6i) and myotube number (Fig. 6j), and a rescue
in the phenotype by irisin was not observed. Our results therefore
suggest that irisin may partly signal through IL6 to enhance
proliferation and differentiation and hence, skeletal muscle
hypertrophy.
Irisin promotes satellite cell activation and expansion. We next
tested the efﬁcacy of irisin in improving skeletal muscle regen-
eration. Immunohistochemical analysis on muscle sections with
MyoD antibodies (a marker of activated satellite cells) revealed
increased percentage of MyoD-positive cells on day 2 and day 3
post-notexin-induced injury in mice injected with irisin, when
compared to DB-injected controls (Fig. 7a, b).
To assess if irisin directly activates satellite cells, primary
murine satellite cells were cultured, treated with recombinant
irisin protein, and subjected to immunocytochemistry to assess the
populations of cells positive for Pax7 and MyoD. The percentages
of Pax7+/MyoD− (quiescent satellite cells), Pax7+/MyoD+ (pro-
liferating myoblasts), and Pax7−/MyoD+ (committed myoblasts)
cells were assessed in cultures treated with either DB or
recombinant irisin protein (Fig. 7c). Treatment with irisin resulted
in a marked reduction in the percentage of quiescent satellite cells
(Pax7+/MyoD−) (Fig. 7d), concomitant with an increase in the
percentages of proliferating (Pax7+/MyoD+) (Fig. 7e) and
committed myoblasts (Pax7−/MyoD+) (Fig. 7f). These data suggest
that irisin treatment leads to increased satellite cell activation and
proliferation.
Irisin induces hypertrophy during muscle regeneration. Next
we assessed the effect of irisin treatment on resulting muscle ﬁber
size and centrally formed nuclei in regenerated skeletal muscle.
Subsequent analysis of muscle ﬁber CSA revealed more myoﬁbers
with larger (> 1500 μm2) CSA, concomitant with a reduction in
myoﬁbers with smaller (< 1500 μm2) CSA in regenerated muscle
subjected to irisin injection, when compared to DB-injected
controls (Fig. 7g, h), thus conﬁrming that irisin injection leads to
hypertrophy of skeletal muscle. Consistent with the hypertrophy
phenotype seen in the regenerated skeletal muscle, and with the
enhanced fusion noted previously (Fig. 2b, d), we observed an
increase in the percentage of regenerated myoﬁbers that con-
tained two centrally formed nuclei, with a concomitant decrease
in the percentage of myoﬁbers with one centrally formed nuclei,
in mice injected with recombinant irisin protein (Fig. 7i).
Irisin rescues denervation-induced atrophy. To investigate if
irisin can alleviate muscle atrophy, we utilized a model of
denervation-induced atrophy. We observed a signiﬁcant increase
in the average body weight of irisin-injected mice at the initial
stage (Fig. 8a). Overall, mice injected with irisin showed a greater
percentage increase in body weight (~ 13.7%), when compared to
DB-injected mice (~ 12.2%) during the trial (Fig. 8b). However,
this difference was not statistically signiﬁcant. Comparison of
muscle weights revealed a signiﬁcant increase in denervated M.
gastrocnemius (Gas) (p< 0.01) and soleus (Sol) (p< 0.05) muscle
weights (Fig. 8c) upon irisin injection. We also noted an increase
in the denervated TA muscle after irisin injection, although sta-
tistically insigniﬁcant. A signiﬁcant increase in the denervated
muscle mass after irisin injection suggested that irisin may have
an important role in rescuing skeletal muscle atrophy.
We next performed histological analysis to quantify myoﬁber
CSA in both non-denervated and denervated irisin- and DB-
injected mice (Fig. 8d). Subsequent analysis of myoﬁber CSA
conﬁrmed that irisin injection leads to hypertrophy of skeletal
muscle ﬁbers (Fig. 8e, f). Consistent with the atrophy model,
denervation leads to reduced myoﬁber CSA (Fig. 8e, f). Due to
sciatic nerve injury a considerable increase in the number of
smaller muscle ﬁbers (< 1000 µm2), concomitant with a decrease
in larger muscle ﬁbers (> 1500 µm2) was observed in TA muscles
of DB-injected mice (Fig. 8e, f). Consistent with the increase in
muscle weights observed in irisin-injected mice (Fig. 8c), we
noted a signiﬁcant increase in the numbers of larger muscle ﬁbers,
with a concomitant decrease in smaller ﬁbers, in irisin-treated
denervated mice, when compared to denervated DB-treated
controls (Fig. 8e, f). In agreement with this, the average TA
muscle area of irisin-injected denervated mice was signiﬁcantly
(p< 0.01) increased, when compared to DB-injected denervated
mice (Fig. 8g).
Fig. 2 Irisin promotes skeletal muscle differentiation. a Graph showing the absorbance readings of cells treated with DB (control) or increasing
concentrations of irisin (250, 1000, and 2000 ng/ml) at 0, 24, 48, and 72 h of proliferation. Absorbance reading at 655 nm is proportional to the number
of cells present and hence, indicative of myoblast proliferation. (n= 16 biological replicates). b Representative images of H&E-stained myoblasts at 0, 24,
48, 72, and 96 h of differentiation in the presence of DB (control) or irisin (250 and 1000 ng/ml). c Graph showing quantiﬁcation of myotube number at 0,
24, 48, 72, and 96 h of differentiation in the presence of DB (control) or irisin (250 and 1000 ng/ml) (n= 3 biological replicates). d Graph showing
quantiﬁcation of fusion index at 0, 24, 48, 72, and 96 h of differentiation in the presence of DB (control) or irisin (250 and 1000 ng/ml) (n= 3 biological
replicates). Graphs displaying qPCR analysis of e myomaker and f caveolin-3 expression normalized to GAPDH in differentiating myoblasts (0, 24, 48, 72,
and 96 h) treated with DB (control) or irisin (1000 ng/ml) (n= 3 biological replicates). g IB analysis of MyoD, MHC, myogenin, and p21 protein levels. The
levels of GAPDH were assessed as a loading control. Graphs show densitometric analysis of hMyoD, iMHC, j myogenin, and k p21 levels in arbitrary units
(a.u), normalized to GAPDH (n= 3 biological replicates). Since MyoD, MHC, and myogenin IB analysis was performed on the same membrane, the same
GAPDH was used to normalize the results. All IBs were performed on proteins collected from differentiating myotubes at 24, 48, 72, and 96 h treated with
either DB (control) or irisin (1000 ng/ml). Error bars represent mean± SEM. One-way ANOVA was performed for all relevant ﬁgure panels between a and
d, and Student’s t-test was performed for all relevant ﬁgure panels between e and k. Signiﬁcance is indicated with *p< 0.05 and **p< 0.01
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Skeletal muscle injury leads to activation of satellite cells, which
function to repair and regenerate skeletal muscle tissue. As such,
we next performed immunocytochemistry on TA muscle sections
to determine the numbers of nuclei positive for MyoD (a marker
of activated satellite cells) (Fig. 9a). Subsequent quantiﬁcation
revealed a signiﬁcant increase in the numbers of MyoD-positive
nuclei, consistent with increased satellite cell activation, in irisin-
injected denervated TA muscle, when compared to respective
DB-injected controls (Fig. 9b). These data suggest that irisin
treatment results in increased activation of satellite cells during
denervation-induced skeletal muscle atrophy.
Atrogin-1 and MuRF-1 are two E3 ubiquitin ligases that are
used as reliable markers for protein degradation during atrophic
conditions, including denervation25. Therefore, we next measured
the protein levels of both Atrogin-1 and MuRF-1 in Gas muscle
isolated from non-denervated, denervated DB-injected mice,
and denervated irisin-injected mice. As expected, we observed a
signiﬁcant increase in Atrogin-1 (Fig. 9c, d) and MuRF-1
(Fig. 9e, f) protein levels in response to denervation-induced
skeletal muscle atrophy. However, injection of irisin resulted in a
notable reduction in Atrogin-1 (Fig. 9c, d) and MuRF-1 (Fig. 9e,
f) protein levels in denervated muscle, when compared to muscle
isolated from denervated, DB-injected mice. These data suggest
that irisin treatment leads to reduced expression of key markers
of skeletal muscle wasting during denervation-induced muscle
atrophy.
Discussion
Irisin is a novel myokine10 that has been shown to induce
browning of white adipocytes. However, the endocrine/paracrine
function of this myokine on skeletal muscle during postnatal
myogenesis is still uncharacterized. We reasoned that irisin could
improve myogenesis and/or induce hypertrophy of skeletal
muscle since irisin is an exercise-induced factor. Our ﬁndings are
consistent with this hypothesis and the extended results here
provide an exempliﬁcation of the therapeutic beneﬁts of irisin in
improving muscle healing after injury and alleviating atrophy of
skeletal muscle in mouse models.
For this study we have used Escherichia coli-puriﬁed recom-
binant irisin protein with low levels of endotoxin. It is also
important to note that after irisin injection, mice did not show
any adverse reaction or notable change in movement, food, or
water intake. Furthermore, no signiﬁcant pathology or toxicity
was observed in any major organ system. No signs of inﬂam-
mation or ﬂuid retention in any part of the body was seen. Hence,
we believe the recombinant protein was non-toxic.
As expected, the recombinant irisin protein used in this study
was able to increase the expression of Ucp1 in white adipocyte
cultures (Fig. 1b, c), as well as increased Ucp1 protein expression
levels in subcatenous adipose tissue (Fig. 4b) conﬁrming that it is
biologically active. Recently, it has been reported that human
irisin is glycosylated26. Since E. coli-expressed proteins are not
glycosylated, it is possible that the recombinant irisin protein that
we have used may not be fully active26.
We used this validated protein to monitor the effect of irisin on
skeletal muscle. Since irisin is a secreted myokine, which is shown
to be a systemic factor27, we either injected mice with recombi-
nant irisin protein or treated myogenic cultures with recombinant
irisin protein, to monitor the biological effect of irisin on skeletal
muscle both in vitro and in vivo. Several lines of evidence suggest
that irisin is a pro-myogenic factor. Microarray analysis and
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subsequent qPCR validation revealed that several negative reg-
ulators of myogenesis, such as sox8, heyL, and ogn were down-
regulated, while pro-myogenic factors, such as sema3f, il6, shq1,
il7, erpina3g, bmp4, tnfrsf11b, and agxt2, were upregulated in
response to irisin treatment (Fig. 1 and Table 1). It is also
interesting to note that irisin treatment led to a signiﬁcant
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increase in a number of genes associated with exercise, which is
consistent with the hypothesis that irisin is an exercise-induced
myokine that may impart beneﬁts of exercise on skeletal muscle.
Furthermore, exogenous addition of irisin improved myogenic
differentiation in myoblasts, as quantitative analysis revealed
increased myotube number and myotube fusion index in
response to irisin treatment. It is noteworthy that murine irisin
was also able to induce myogenesis in human primary myoblast
cultures. Although we have not directly addressed the issue
whether human irisin can induce myogenesis in human myo-
blasts, the preliminary results presented here allude to the exis-
tence of a receptor that can bind to irisin-like molecule on human
myoblasts. Further work is required to purify recombinant
human irisin and fully characterize its bioactivity on human
myoblasts.
The enhanced myogenesis in C2C12 cultures due to irisin
treatment appears to be due to increased fusion of myoblasts, as
irisin upregulated the expression of myomaker28 and caveolin-329,
two genes previously shown to be required for myoblast fusion.
Consistent with what we observed in vitro, when irisin protein
was injected during muscle regeneration, we observed an increase
in MyoD-positive proliferating myoblasts at day 2 and day 3 post
injury. Our analysis further indicated that irisin treatment
enhanced the pool of proliferating (Pax7+/MyoD+) and fusion
competent (Pax7−/MyoD+) myoblasts in primary myoblast cul-
tures. Following regeneration we also observed an increase in
myoﬁber CSA along with an increase in the numbers of myoﬁbers
that contain two centrally formed nuclei. These data support that
irisin promotes improved fusion of satellite cell-derived myo-
blasts, leading to hypertrophy of skeletal muscle. Therefore, taken
together, in vitro and in vivo results reveal that irisin could
potentially improve myogenesis through not only increasing the
fusion competent myoblast pool but also through enhancing
myoblast fusion capacity.
Both microarray analysis and subsequent real-time PCR ana-
lysis conﬁrmed that irisin is a potent inducer of IL6. It has been
previously shown that IL6 levels are induced during myogenic
differentiation30, and that absence of IL6 mRNA reduced myo-
genic differentiation while overexpression of IL6 mRNA
enhanced myogenic differentiation30. Much like irisin, IL6 is
secreted by skeletal muscle during exercise31 and IL6 has also
been identiﬁed as an essential regulator of skeletal muscle
hypertrophy via satellite cell activation32. Furthermore, absence of
IL6 reduced muscle hypertrophy and satellite cell proliferation in
a Stat3-dependent manner32. All these circumstantial evidence
made IL6 a very good downstream target of irisin. Consistent
with this theory, we observed that irisin is a potent inducer of IL6
in both myoblasts and myotubes, and that knocking down of IL6
resulted in impaired ability of irisin to induce myogenesis.
Therefore, we propose that at least in part, irisin signals via IL6 to
promote myogenesis.
Since irisin is an exercise mimetic, we investigated if irisin can
induce an exercise phenotype in mouse muscles. Wild-type mice
injected with irisin showed increased body weights, which could
be attributed to increased skeletal muscle mass. Irisin injection
further resulted in improved muscle strength, which was reﬂected
by an increase in grip strength. Subsequent CSA analysis revealed
a signiﬁcant hypertrophy phenotype in muscle of mice injected
with irisin. Taken together, these observations are consistent with
typical changes noted in response to resistance exercise. However,
none of the effects of irisin on skeletal muscle in vivo could be
recapitulated with a control peptide or vehicle control (DB).
Hypertrophy of skeletal muscle could occur via three mechan-
isms: increased protein synthesis4, 5; reduced protein
degradation25, 33; and increased satellite cell activation34. Irisin
injection resulted in a signiﬁcant increase in the numbers of
activated myoblasts and further enhanced myoblast fusion during
regeneration. Furthermore, we observed increased IL6, p-Akt, and
p-Erk1/2 levels, concomitant with reduced p-Raptor levels
upon treatment with irisin, which are indicative of increased
protein synthesis. In addition to increased protein synthesis we
have further noted reduced protein degradation upon irisin
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treatment. Speciﬁcally, we noted increased expression of hap-
toglobin upon irisin treatment. Interestingly, previous work has
revealed that absence of haptoglobin resulted in skeletal muscle
atrophy, both through upregulating atrophy markers, such as the
E3 ligases Atrogin-1, and MuRF-1, and via downregulating pro-
tein synthesis35. Thus, it is interesting to surmise that in addition
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to promoting protein synthesis, irisin may also prevent excess
skeletal muscle protein turnover through enhancing haptoglobin
levels. In agreement with reduced protein turnover, we observed
reduced Atrogin-1 and MuRF-1 levels upon irisin treatment. The
levels of Atrogin-1 and MuRF-1 are regulated by FoxO tran-
scription factors and hence we expected to observe a signiﬁcant
increase in the phosphorylation status of FoxO1, which equates to
inactivation of FoxO1, upon irisin treatment. Although we see a
trend of increased levels of p-FoxO1, the increase was not sta-
tistically signiﬁcant. This suggests that irisin may decrease the
levels of Atrogin-1 and MuRF-1 through additional mechanisms.
It is quite possible that regulation of additional upstream med-
iators of Atrogin-1 and MuRF-1 expression, such as nuclear
factor-κB36, myostatin/transforming growth factor-β signaling33,
and p38 MAPK37 may play a role in irisin regulation of protein
degradation. Taken together these data suggest that irisin pro-
motes skeletal muscle hypertrophy by shifting the balance toward
increased protein synthesis and reduced protein breakdown.
To further prove the pro-myogenic function of irisin we next
assessed the utility of irisin injection in overcoming the severe
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atrophy associated with denervation. Sciatic nerve transection
leads to denervation of skeletal muscle and severe skeletal muscle
atrophy through activation of components of the ubiquitin pro-
teosome pathway, including Atrogin-1 and MuRF-1. Previous
studies have shown that exercise is able to rescue skeletal muscle
atrophy through promoting an increase in lean muscle mass38.
Here we show that injection of irisin was able to partially rescue
the atrophic phenotype observed in a mouse model of
denervation-induced atrophy. Mechanistically, we propose that
irisin injection leads to increased activation of satellite cells
(Fig. 7a–c, e, f) and reduces protein degradation by reducing
Atrogin-1 and MuRF-1 (Fig. 9c–f) resulting in a partial rescue of
atrophy.
In the present study we have assessed the function of irisin in
regulating muscle growth in mice. For this purpose we have used
murine irisin to exemplify that irisin induces hypertrophy and
also promotes myogenesis. Although we were able to partially
recapitulate the effects of resistance exercise such as hypertrophy
on skeletal muscle through irisin treatment, it is important to
highlight that we did not compare the extent of hypertrophy
between resistance exercise and irisin-induced hypertrophy.
Furthermore, in the light of recent conﬁrmation of the presence
of human irisin protein in circulation, and the fact that irisin
levels are increased in humans in response to exercise18, further
work needs to be undertaken to conﬁrm the biological effects of
human irisin in human skeletal muscle.
Methods
Expression and puriﬁcation of recombinant irisin protein. Recombinant
M-irisin was expressed and puriﬁed using the pET expression system (Novagen).
M-irisin cDNA (encoding aa 29–140 of FNDC5) was PCR-ampliﬁed and cloned
into pET-16b expression vector in frame with 10 histidine residues using standard
molecular biology techniques. The resulting construct was transformed into E. coli
strain BL21 (Agilent Technologies, USA) and was cultured in Lennox broth (LB)
containing ampicillin (100 mg/l) overnight as starter culture. The starter culture
was diluted into 4 l of LB medium plus ampicillin and was further grown to an OD
of 0.8 at 595 nm. Bacteria were then induced to produce histidine-tagged irisin
through addition of 1 mM isopropyl-1-thio-β-D-glalactopyranoside for 2.5 h. Bac-
teria were harvested by centrifugation, resuspended in 100 ml of binding buffer
(50 mM Tris-HCl (pH 8.0), 200 mM NaCl, 10% glycerol, and 20 mM imidazole)
and sonicated. The lysate was centrifuged for 30 min at 10,000×g and the super-
natant was collected and run through a Ni-NTA agarose afﬁnity column (Qiagen)
for recombinant irisin puriﬁcation, according to the manufacturer’s protocol.
Fractions containing recombinant irisin protein eluted from the Ni-NTA agarose
column were pooled and dialyzed against three changes of DB (50 mM Tris-HCl
(pH 8.0), 500 mM NaCl, and 10% glycerol) for a period of 3 h. Endotoxin level in
recombinant irisin protein was estimated by ToxinSensor Chromogenic LAL kit
(GenScript, USA) according to the manufacturer’s protocol.
Animals. Wild-type C57BL/6J male mice used in the study were obtained from
either Nanyang Technological University (NTU) Animal house, A*STAR Biolo-
gical Resource Centre, Singapore or InVivos, Singapore. All experiments were
performed on 5- to 8-week-old mice according to the Institutional Animal Care &
Use Committee (IACUC)-approved protocols. IACUC granted permission to
perform all animal experiments in this manuscript. All mice were maintained on
standard chow diet at a constant temperature of 20 °C under an artiﬁcial 12 h light
and 12 h dark cycle with ad libitum access to water at the NTU animal house. To
assess pro-myogenic function of irisin, 5-week-old C57BL/6J mice were injected
with 2.5 μg/g body weight of irisin twice a week intraperitoneally (IP) for 4 weeks
and control animals were injected with DB, vehicle control. For control peptide
animal trial, we used N-terminal His-tag of recombinant irisin fusion protein
coded by the pET-16b vector. The 20-aa-long peptide (MGHHHHHHHHHHS
SGHIEGR) was synthesized by Merck, Sigma-Aldrich. Similar to the irisin previous
animal trial, 5-week-old C57BL/6J mice were injected with 2.5 μg/g body weight of
His-tag peptide thrice a week IP for 4 weeks and control animals were injected with
DB as vehicle control. Body weight and food consumption were measured during
animal trial. Following the trial, mice were sacriﬁced by CO2 asphyxiation and
various skeletal muscle tissues were collected for further experiments. TA muscle
tissue was embedded in optimal cutting temperature compound (OCT) (Sakura
Finetek, USA), frozen in liquid nitrogen-cooled isopentane, and stored at −80 °C
for subsequent sectioning and staining.
Injury of resting muscle was performed through injection of notexin. A unit of
100 µg of notexin powder (Latoxan, L8104) was dissolved in 1 ml of autoclaved
saline and diluted to 10 µg/ml before injection. Mice were anesthetized through IP
injection of a mixture of ketamine and xylazine at 0.1 ml/10 g of body weight. A
volume of 15 µl of 10 µg/ml notexin was injected along the longitudinal axis of left
TA muscles of 6-week-old C57BL/6J wild-type mice39. The right TA muscle was
used as an uninjured control. Mice were injected IP with DB or recombinant irisin
protein (2.5 µg/g body weight) three times a week, 1 week prior to the injury, and
also following notexin injury for the duration of the trial. TA muscles were
collected and OCT-embedded as mentioned above from mice at days 1, 2, 3, and 10
post-notexin-induced injury.
In order to investigate if irisin reduces the atrophy of skeletal muscle, 8-week-
old C57BL/6J male mice were anesthetized through IP injection of a mixture of
ketamine and xylazine at 0.1 ml/10 g of body weight. Hair on the hindlimb was
shaved using an electric shaver. A small incision was made and the sciatic nerve of
the left leg was isolated and cut using surgical scissors. The skin was glued to close
the wound. The contralateral (right) leg was used as the uninjured control. Mice
were IP-injected with either DB or irisin (2.5 µg/g body weight) for 1 week prior to
injury and 2 weeks post injury, at a frequency of three times a week. Following
conclusion of the trial, mice were sacriﬁced by CO2 asphyxiation and various
skeletal muscle tissues were collected for further experiments. TA muscle tissue was
embedded in OCT (Sakura Finetek), as mentioned above for subsequent sectioning
and staining.
Detection of irisin in serum. Blood collected from mice injected with DB or irisin
twice a week for 4 weeks were incubated at room temperature (RT) for 30 min.
Blood samples were then centrifuged at 1500×g for 15 min at 4 °C and serum was
isolated. Irisin levels in the serum were quantiﬁed using a commercial ELISA kit
following the manufacturer’s protocol (Irisin ELISA kit EK-067−52, Phoenix
Pharmaceuticals, Inc., USA) using spectrophotometry at a wavelength of 450 nm.
The detection range of the kit is 0.1–1000ng/ml.
Muscle ﬁber CSA measurement. Transverse sections (10 µm) were cut from the
mid-belly region of OCT-embedded TA muscle using a cryostat (Leica CM 1950,
Germany) and sections were stained with Gill’s hematoxylin followed by 1% eosin
(Merck; H&E). TA muscle sections were photographed and tiled using the Leica
CTR 6500 microscope equipped with the Leica DFC 420 camera and Image Pro
Plus software (Media Cybernetics, Bethesda, MD, USA). The CSA of 200 muscle
Fig. 7 Irisin improves regeneration of skeletal muscle. a Representative images of MyoD immunostaining of TA muscle sections from DB (control)- or
irisin-injected mice at day 2 and day 3 post notexin injury. Images were captured using a ×40 objective. Scale bar represents 100 μm. Nuclei were
counterstained with DAPI. White asterisks denote MyoD-positive cells. Linear brightness and contrast of ‘Merge’ panel was adjusted to visualize MyoD+
cells without altering the interpretation of results in any way. b Graph displaying the percentage of MyoD-positive cells in TA muscle sections from DB
(control)- or irisin-injected mice at day 2 (n= 3 mice for both groups) and day 3 (n= 2 mice for control group and n= 3 mice for irisin-injected group) post
notexin injury. c Representative images of MyoD and Pax7 immunostaining of primary satellite cell cultures treated with either DB (Control) or irisin (1000
ng/ml) for 24 h. Linear brightness and contrast of “Dapi”, “Pax7”, and “MyoD” panels was adjusted to visualize the positively stained nuclei without
altering the interpretation of results in any way. Images were captured using a ×10 objective. Scale bar represents 100 μm. Graphs displaying the
percentage of d quiescent (Pax7+/MyoD−), e proliferating (Pax7+/MyoD+), and f committed (Pax7−/MyoD+) satellite cells present following treatment
with either DB (control) or increasing concentrations of irisin (250, 700, and 1000 ng/ml) for 24 h (n= 2 biological replicates). g Representative images of
H&E-stained TA muscle at day 10 post notexin injury from mice injected with either DB (control) or irisin. Images were captured using a ×20 objective.
Scale bar represents 100 μm. h Graphs showing the distribution of TA myoﬁber cross-sectional area (CSA) and the i percentage of myoﬁbers with 1, 2, 3, or
4 centrally placed nuclei at day 10 post notexin injury from mice injected with either DB (control) or irisin (2.5 μg/g of body weight) (n= 3 mice for both
groups). Error bars represent mean± SEM. Student’s t-test was performed for b, h, i, and one-way ANOVA was performed for d–f. Signiﬁcance is indicated
with *p< 0.05, **p < 0.01 and ***p< 0.001
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ﬁbers from 5 random ﬁelds (1000 ﬁbers per section per mouse) were analyzed
(n= 3 mice per treatment group).
Immunohistochemical staining of muscle sections. Muscle sections were ﬁxed
with 4% paraformaldehyde in phosphate-buffered saline (PBS) (pH 7.4) for 10 min
and then permeabilized with 0.1% Triton X-100 for 10 min. Sections were blocked
with 5% normal sheep serum (NSS), 5% normal goat serum (NGS), and 0.35%
Carrageenan lambda (Cλ) in PBS for 1 h at RT and incubated with anti-MyoD (SC-
304, 1:50) primary antibody overnight at 4 °C. Sections were then incubated with
secondary antibody (Alexa Fluor 568 goat anti-rabbit 1:300) for 1 h at RT. Sections
were counterstained with 4,6-diamidino-2-phenylindole (DAPI) (1:1000) for 5 min
in PBS and mounted using Prolong Gold Anti-Fade (Thermo Fisher Scientiﬁc,
USA). Stained samples were analyzed and MyoD-positive nuclei were counted,
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with the number of MyoD-positive nuclei expressed as a percentage of total DAPI-
positive nuclei. Images from 20 random microscopic ﬁelds for each treatment were
analyzed per mouse using the Leica CTR 6500 microscope equipped with the Leica
DFC 420 camera and Image Pro Plus software (Media Cybernetics).
Cell culture. American Type Culture Collection (ATCC) murine C2C12 myoblasts
(Yaffe and Saxel, 1977)40 were maintained in proliferation medium, consisting of
Dulbecco’s modiﬁed Eagle’s medium (DMEM) (Invitrogen, Carlsbad, CA, USA),
10% fetal bovine serum (HyClone, Thermo Scientiﬁc, USA), and 1% penicillin/
streptomycin (P/S) (Gibco, Invitrogen). 36C15Q primary human myoblasts were a
gift from Drs. Vincent Mouly and Gillian Butler-Browne from the Institut de
Myologie and were maintained in proliferation medium, consisting of DMEM, 20%
fetal bovine serum, 10% horse serum (HS), 1% chick embryo extract (CEE),
and 1% P/S.
C2C12 myoblasts were seeded at a density of 1000 cells/well in 96-well plates in
proliferation media and incubated at 37 °C in 5% CO2 incubator. Proliferating
myoblasts were treated with DB or recombinant irisin protein (250, 1000, and
2000 ng/ml) and ﬁxed at 0, 24, 48, and 72 h. The time when myoblasts were
attached was taken as 0 h. Myoblasts were ﬁxed with 200 µl of ﬁxative solution per
well (10% formaldehyde (Sigma-Aldrich, USA) and 0.9% NaCl). Plates were
wrapped in aluminum foil and stored at RT till all plates were ﬁxed. Proliferation
was assessed using the methylene blue photometric end point assay41 where
absorbance at 655 nm is directly proportional to the total cell number. Each
treatment for each time point was conducted in 16 wells.
C2C12 myoblasts were seeded on plastic thermanox cover slips (Nalge Nunc
International, USA) in 24-well-plates at a density of 15,000 cells/cm2 while 36C15Q
primary human myoblasts were seeded at a density of 25,000 cells/cm2. After
overnight cell attachment myoblasts were differentiated with low-serum
differentiation medium (DMEM with 2% HS (Hyclone, Thermo Scientiﬁc, USA)
and 1% P/S) at 37 °C, 5% CO2 and were treated with either DB or recombinant
irisin protein (250 or 1000 ng/ml) during differentiation. After 0, 24, 48, 72, and
96 h of differentiation, myotubes were ﬁxed with 70% ethanol, formalin, and acetic
acid in a 20:2:1 ratio and washed with 1 ml of PBS three times before H&E staining.
Images of non-overlapping areas from three coverslips were taken in a bright-ﬁeld
microscope per time point (Leica CTR 6500 microscope equipped with the Leica
DFC 420 camera). To analyze myotube number 10 random images were obtained
per coverslip at a ×10 magniﬁcation and the total number of myotubes was counted
in each image. Fusion index was measured by dividing the number of nuclei found
within the myotubes by the total number of nuclei in each image.
Primary cultures were isolated from mouse hindlimb muscle tissue. Muscle
tissues collected from wild-type mice were minced well in PBS and centrifuged for
10 min at 3000 r.p.m. to remove the PBS. Minced muscles were resuspended in
ﬁlter sterilized 0.2% Collagenase Type IA (Sigma-Aldrich, USA) in DMEM and
incubated at 37 °C for 90 min on a shaker at 70 r.p.m. (slow shaking). The
suspension was centrifuged at 3000 r.p.m. for 10 min. The pellet was resuspended
in 12 ml of PBS and strained with a 100 µm nylon cell strainer (BD Falcon, USA).
The ﬁltered suspension was further centrifuged at 3000 r.p.m. for 10 min and the
pellet was resuspended in warm satellite cell proliferation media (DMEM, 20%
FBS, 10% HS, 1% CEE (Biomed Diagnostics, Singapore), and 1% P/S). The
suspension was pre-plated on a non-coated 10 cm dish and left at 37 °C and 5%
CO2 for 3 h for removal of ﬁbroblasts from the culture. Subsequently, the
“ﬁbroblast-free” cell suspension was plated onto a 10 cm cell culture dish coated
with 10% Matrigel (Corning, USA) and incubated overnight at 37 °C, 5% CO2.
After overnight attachment, primary myoblasts were trypsinized and seeded at a
density of 10,000 cells/well in 8-well chamber slides (Thermo Fisher Scientiﬁc)39.
Primary myoblasts cultures were treated with recombinant irisin protein (250, 700,
or 1000 ng/ml) and were ﬁxed at 24 h post irisin treatment with 4%
paraformaldehyde in PBS for 15 min. Fixed primary myoblasts were then treated
with 0.1% Triton X-100 for 10 min to permeabilize the cells. Cells were blocked
with 5% NSS, 5% NGS, and 0.35% Cλ in PBS for 1 h at RT and incubated with
primary antibodies, anti-Pax7 (DSHB AB-528428) (1:100), and anti-MyoD (Santa
Cruz, SC-304) (1:100) overnight at 4 °C. After washing, myoblasts were incubated
with secondary antibody (sheep anti-mouse IgG biotinylated (1:300)) for 1 h at RT.
Finally, cells were treated with tertiary antibody (streptavidin-conjugated Alexa
Fluor 488 (1:400) and goat anti-rabbit Alexa Fluor 594 (1:300)) for 1 h at RT in the
dark. DAPI staining was performed for 5 min (1:1000 dilution in PBS) and slides
were mounted using Prolong Gold Anti-Fade. Stained samples were analyzed for
the numbers of Pax7+ and MyoD+ myoblasts. Images from 20 random microscopic
ﬁelds per treatment were analyzed using the Leica CTR 6500 microscope (×10
objective) equipped with the Leica DFC 420 camera and Image Pro Plus software
(Media Cybernetics).
IL6 targeting siRNA (IL6 siRNA) or control non-targeting siRNA (scramb-
siRNA) (Dharmacon, Inc., USA) were transfected into C2C12 myoblasts for 24 h
using DharmaFECT 1 transfection reagent according to the manufacturer’s
protocol. Following transfection, C2C12 myoblasts were switched to differentiation
medium and treated with either DB or irisin for 72 h and stained with H&E for
histological analysis. In order to investigate if irisin signals through IL6, IL6 siRNA
and control siRNA (IL6 siRNA) were transfected with DharmaFECT 1 transfection
reagent for 24 h into myoblasts and differentiated for 48 h in differentiation
medium. RNA was extracted from myotubes and real-time PCR was used to
measure gene expression changes as mentioned above.
Human adipose-derived stem cells. Details regarding establishment of the
human primary ADSCs have been described previously42. The collection of white
adipose tissue biopsies and generation of human primary ADSC cultures was
approved by the Domain Speciﬁc Review Board (#2013/00171) of National Uni-
versity Hospital, Singapore. Approximately 1 g of white adipose tissue was digested
with type IA collagenase (1 mg/ml) in bovine serum albumin (20 mg/ml) for 90
min at 37 °C with shaking (120 r.p.m.). The suspension was centrifuged for 10 min
at 800×g and the cell pellet was suspended in 9 ml of red blood cell lysis buffer and
incubated for 10 min. The cells were centrifuged again for 10 min at 800×g and
resuspended in growth medium, consisting of DMEM/F-12 (Gibco, Thermo Fisher
Scientiﬁc), supplemented with 20% FBS and 1% P/S, and subsequently ﬁltered
through a 100 µm nylon cell strainer. The ﬁltrate was further centrifuged for 10 min
at 800×g and the pellet was resuspended with hADSC growth medium. To induce
adipogenic differentiation, hADSC cells were seeded on 10 cm dishes coated with
0.2% gelatin and grown in DMEM/F12, 10% FBS, and 1% P/S. Cells were grown to
conﬂuence and left for 2 days before treatment with induction medium (DMEM/F-
12, 10% FBS, 1% P/S, 0.5 mM IBMX, 1 µM dexamethasone, 200µM indomethacin
and 58µg/ml insulin) containing DB or irisin (4 μg/ml) for 14 days. The induction
medium was then replaced with insulin medium (DMEM/F-12, 10% FBS, 1% P/S,
and 0.01 mg/ml insulin) for another 7 days in the presence of either DB or irisin
(4 μg/ml)
The murine embryonic ﬁbroblast cell line 3T3L1 (ATCC-CL173), which can be
induced to differentiate into adipocytes in culture, was also used in this study.
Adipogenic differentiation was performed as per the previously described
protocol43. 3T3L1 cells were maintained in growth medium consisting of
DMEM+GlutaMAX, 10% bovine calf serum (Gibco, Thermo Fisher Scientiﬁc),
and 1% P/S. To induce adipogenic differentiation, 3T3L1 cells were seeded on 10
cm dishes coated with 0.2% gelatin and grown in DMEM with 2 mM L-glutamine,
10% FBS, and 1% P/S. Cells were grown to conﬂuence for 72 h and kept at that
state for another 48 h to arrest cell division. 3T3L1 cells were then treated with
induction medium (DMEM +GlutaMAX, 10% FBS, 1% P/S, 0.5 mM IBMX, 1 µM
dexamethasone, and 0.01 mg/ml insulin) containing DB or irisin (0.5 μg/ml) for a
further 48 h. The induction medium was then replaced with insulin medium
(DMEM +GlutaMAX, 10% FBS, 1% P/S, and 0.01 mg/ml insulin) for another 48 h
in the presence of either DB or irisin (0.5 μg/ml).
Western blot analysis. A unit of 50 mg of muscle tissue was homogenized in
RIPA buffer (1× PBS, 1% IGEPAL CA-630 (v/v), 0.1% sodium dodecyl sulfate
(SDS) (w/v), 0.5% sodium deoxycholate (w/v)), and 50 mM sodium ﬂuoride) using
the Tissue Lyser II instrument (Qiagen, USA) at 30 Hz (3 × 1 min). For in vitro
experiments, C2C12 cells were re-suspended in protein lysis buffer (1M Tris-HCl
(pH 7.5), 5 M NaCl, 0.5 M EDTA, IGEPAL CA-630, protease inhibitor, and MilliQ
water). C2C12 cells in lysate buffer were syringed 20 times with a 1 ml syringe and
26 gauge needle. Subsequently, both muscle homogenates and C2C12 cells were
centrifuged at 12,000 r.p.m. for 10 min at 4 °C. Protein estimations were done using
Bradford’s assay reagent. For all western blot analyses, 5–20 µg of protein was
Fig. 8 Irisin rescues denervation-induced loss of muscle mass. a Graph showing average body weight (g) of mice injected with either DB (control) or irisin
(2.5 μg/g body weight) three times a week, 1 week prior to, and 2 weeks post transection of the sciatic nerve. Body weights were measured prior to
injection. b Graph showing the percentage change in body weight (from initial) in mice injected with either DB (control) or irisin pre and post sciatic nerve
transection (n= 6 mice for both groups). c Graph displaying average TA, EDL, Gas, and Sol muscle weights of denervated mice injected with either DB
(control) or irisin pre and post sciatic nerve transection. All hindlimb muscle weights were normalized to tibia length (n= 5 mice for DB-injected group and
6 mice for irisin-injected group). d Representative images of H&E-stained TA muscle from non-denervated and denervated mice injected with either DB
(control) or irisin. e Histogram and f line graph showing the distribution of TA myoﬁber CSA in non-denervated and denervated mice injected with either
DB (control) or irisin. g Graph displaying the average total cross-sectional area of TA muscles from denervated mice injected with either DB (control) or
irisin (n= 3 mice for both groups). Error bars represent mean± SEM. Student’s t-test was performed for all relevant ﬁgure panels. Signiﬁcance is indicated
with *p< 0.05 and **p< 0.01
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resolved by SDS-PAGE (NuPage 4–12% gradient Bis-Tris pre-cast polyacrylamide
gels, Invitrogen) and transferred to nitrocellulose membrane by electroblotting.
The following primary antibodies were used for western blotting: MyoD (1:500, sc-
304, Santa Cruz); myogenin (1:400 sc-576, Santa Cruz); p21 (1:200, 556430, BD
Pharmingen); MHC (MF-20) (1: 400, DSHB); Akt1/2/3 (1:500, sc-8312, Santa
Cruz); p-Akt (S473) (1:500, sc-7985, Santa Cruz); Erk1/2 (1:500, sc-292838, Santa
Cruz); p-Erk (1:500, sc-16982, Santa Cruz); Raptor (1:500, 4978, Cell Signalling); p-
Raptor (S792) (1:500, 2083, Cell Signalling); p-FoxO1 (1:500, sc-101681, Santa
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Fig. 9 Irisin treatment rescues denervation-induced muscle atrophy. a Representative images of MyoD immunostaining of TA muscle sections from
denervated mice injected with either DB (control) or irisin. Images were captured using a ×20 objective. Scale bar represents 100 μm. Nuclei were
counterstained with DAPI. White asterisks denote MyoD-positive cells. Linear brightness and contrast of ‘Merge’ panel was adjusted to visualize MyoD+
nuclei without altering the interpretation of results in any way. b Graph displaying the percentage of MyoD-positive cells in TA muscle sections from
denervated mice injected with either DB (control) or irisin pre and post sciatic nerve transection. c IB analysis of Atrogin-1 protein levels in Gas muscle
from non-denervated mice injected with DB (control) and denervated mice injected with either DB (control) or irisin. The levels of GAPDH were assessed
as a loading control. Arrow indicates Atrogin-1 band. d Graph shows densitometric analysis of Atrogin-1 levels in arbitrary units (a.u), normalized to
GAPDH. e IB analysis of MuRF-1 protein levels in Gas muscle from non-denervated mice injected with DB (control) or denervated mice injected with either
DB (control) or irisin. The levels of GAPDH were assessed as a loading control. f Graph shows densitometric analysis of MuRF-1 levels in a.u, normalized to
GAPDH (n= 3 biological replicates). Error bars represent mean± SEM. Student’s t-test was performed for b and one-way ANOVA was performed for d
and f. Signiﬁcance is indicated with *p< 0.05 and **p< 0.01
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Cruz); FoxO1 (1:500, sc-11350, Santa Cruz); MAFbx/Atrogin-1 (1:500, PAB15627,
Abnova); MuRF-1 (1:1000, gift from Regeneron); GAPDH, 1:10,000 dilution of
puriﬁed mouse monoclonal anti-GAPDH antibody (G9545, Sigma-Aldrich); and
α-tubulin, 1:10,000 dilution of puriﬁed mouse monoclonal antibody (T5168,
Sigma-Aldrich). Uncropped scans of western blots are shown in Supplementary
Figs. 1–5.
Quantitative real-time PCR. Total RNA was isolated from C2C12 myotubes using
TRIzol reagent (Invitrogen), according to the manufacturer’s instructions. RNA
integrity was monitored by RNA electrophoresis. A unit of 1 μg of total RNA was
used to synthesize cDNA according to the iScript cDNA Synthesis kit protocol
(Bio-Rad). qPCR reactions were carried out in triplicates using SsoFast EvaGreen
Supermix (Bio-Rad) and the CFX96 Real-Time System (Bio-Rad). All reactions
were performed using the following thermal cycle conditions: 95 °C for 3 min,
followed by 40 cycles of a three-step reaction, denaturation at 95 °C for 10 s,
annealing at 60 °C for 10 s, elongation at 72 °C for 20 s, followed by a melting curve
from 65 to 95 °C in 10 s increment of 0.5 °C. Gene expression fold change was
calculated using the ΔΔCt method, normalized against the expression of Gapdh.
Primers stocks (100 μM; Sigma-Aldrich, Singapore) were diluted to 2.5 μM prior to
qPCR. The sequences of the primers used in this study are provided below:
Caveolin 3-F: 5ʹ-GA TCT GGA AGC TCG GAT CAT-3ʹ, Caveolin 3-R: 5ʹ-TCC
GCA ATC ACG TCT TCA AAA T-3ʹ;Myomaker-F: 5ʹ-GAC AGT GAG CAT CGC
TAC CA-3ʹ, Myomaker-R: 5ʹ-GTT CAT CAA AGT CGG CCA GT-3ʹ; GAPDH-F:
5ʹ-ACA ACT TTG GCA TTG TGG AA-3ʹ, GAPDH-R: 5ʹ-GAT GCA GGG ATG
ATG TTC TG-3ʹ; Sox8-F: 5ʹ-CTG TGG CGC TTG CTG AGT-3ʹ, Sox8-R: 5ʹ-CGG
CCA GTC TTC ACA CTC TT-3ʹ; Heyl-F: 5ʹ-TGC CTT TGA GAA ACA GGC T-
3ʹ, Heyl-R: 5ʹ-AGG CAT TCC CGA AAC CCA AT-3ʹ; Haptoglobin-F: 5ʹ-TTC TAC
AGA CTA CGG GCC GA-3ʹ, Haptoglobin-R: 5ʹ-CCC ACA CAC TGC CTC ACA
TT-3ʹ; IL6-F: 5ʹ-GGG ACT GAT GCT GGT GAC AA-3ʹ, IL6-R: 5ʹ-TGC CAT TGC
ACA ACT CTT TTC T-3ʹ; CXCL1-F: 5ʹ-CCG AAG TCA TAG CCA CAC TCA-3ʹ,
CXCL1-R: 5ʹ-GTG CCA TCA GAG CAG TCT GT-3ʹ; Ptx3-F: 5ʹ-CCC GCA GGT
TGT GAA ACA G-3ʹ, Ptx3-R: 5ʹ-TAG GGG TTC CAC TTT GTG CC-3ʹ; Stat3-F:
5ʹ-GGC ACC TTG GAT TGA GAG TC-3ʹ, Stat-3-R: 5ʹ-ACT CTT GCA CCA ATC
GGC TA-3ʹ; Socs3-F: 5ʹ-AAC CCT CGT CCG AAG TCC C-3ʹ, Socs3-R: 5ʹ-TTC
CGA CAA AGA TGC TGG AG-3ʹ.
Microarray analysis. C2C12 myoblasts were seeded at a density of 25,000 cells/
cm2 in a 10 cm cell culture dish and differentiated with low-serum differentiation
medium at 37 °C, 5% CO2 for 72 h and further treated with either DB or recom-
binant irisin protein (1000 ng/ml) for 6, 12, 24, and 48 h. Myotubes were resus-
pended in 2 ml of TRIzol for each 10 cm dish and RNA isolation was performed
according to the manufacturer’s protocol. Puriﬁed isolated RNA was then subjected
to Illumina bead array sequencing and data analysis, as per in-house protocols
(Sciencewerke, Singapore). Only genes that were upregulated or downregulated by
≥1.5-fold were considered signiﬁcant. For genes that had multiple probes (with
different accession number), only one probe with the highest upregulation or
downregulation was taken into consideration.
Statistical analysis. Statistical analysis was performed using two-tailed Student’s
t-test to compare differences between two groups. F-test was performed prior to
Student’s t-test to determine equal variance between the two groups. Variance
between two groups was considered equal when F-value was smaller than F-critical
(type 2 error) and unequal if F-value was larger than F-critical values (type 3 error).
One-way analysis of variance (ANOVA) was performed for all experiments that
require a comparison between three or more groups within one categorical variable
followed by a Tukey’s post hoc test. For experiments requiring the analysis of two
categorical variables that could inﬂuence the numerical output, two-way ANOVA
was performed followed by Scheffe’s post hoc test. For all experiments, results were
considered signiﬁcant at p < 0.05 (*), p < 0.01 (**) and p < 0.001(***). Data are
presented as mean± SEM.
Data availability. All the relevant data are available from the corresponding author
upon reasonable request. Microarray data has been deposited in Array Express
database and the accession number is E-MTAB-6024.
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